Search Results
May 13, 2026, 16:30 ET IceCure Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement
cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective option to surgical tumor removal that is easily performed in a relatively short procedure.
More news about: IceCure Medical
May 13, 2026, 16:05 ET Nuvation Bio to Collaborate with Thermo Fisher Scientific for U.S.-Based Manufacturing of IBTROZI® for ROS1-Positive Non-Small Cell Lung Cancer
patients."About ROS1+ NSCLCEach year, more than one million people globally are diagnosed with non-small cell lung cancer (NSCLC), the most common form of lung cancer. It is estimated that approximately 2% of patients with NSCLC have ROS1+ disease. About 35% of patients newly diagnosed
More news about: Nuvation Bio Inc.
May 13, 2026, 16:00 ET CytoSorbents Reports First Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update
blood pumps already in the hospital (e.g. dialysis, continuous renal replacement therapy or CRRT, extracorporeal membrane oxygenation or ECMO, and heart-lung machines), where blood is repeatedly recirculated outside the body, through our cartridges where toxic substances are removed, and then back into the
More news about: Cytosorbents Corp
May 13, 2026, 13:43 ET Journal of Independent Medicine Releases New Issue Featuring Major Review on Autism Spectrum Disorder and Expanding Global Contributions to Honest Medicine
unavailable.E-cigarette or Vaping Product Use-Associated Lung Injury (EVALI): A Significant Health Crisis in the Digital WorldRubi Thapa, Vivek Paudyal, Samina Somji, Munish Sharma, Salim SuraniReviews the rise of vaping-related lung injury and outlines diagnostic challenges,
More news about: Independent Medical Alliance
May 13, 2026, 12:16 ET Non-Animal Alternative Testing Market Size to Reach $29.4 Billion by 2030, Globally, at 13.5% CAGR: Allied Market Research
accelerated significantly. Emulate, Inc. has attracted approximately $224 million in cumulative funding for its Human Emulation System which models kidney, lung, liver, brain, and intestine functions. CN Bio Innovations raised a $21 million Series B in April 2024. The NIH's July 2025 declaration barring funding
More news about: Allied Market Research
May 13, 2026, 11:49 ET Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1
The sponsorship helps expand proven strategies to consistently detect a genetic, irreversible, and progressive condition in patients with liver and/or lung disease.DURHAM, N.C., May 13, 2026 /PRNewswire/ -- AlphaDetect,
More news about: Alpha-1 Foundation
May 13, 2026, 09:02 ET DELFI Diagnostics to Present First Clinical Utility Data for Blood-Based Lung Cancer Screening at ATS 2026 International Conference
using a blood test for lung cancer screening is that a primary care provider will be able to send their patient down the hall to the lab to get a complete blood count, cholesterol, and lung cancer screening. The hope for a lung cancer screening blood test is that it makes lung cancer screening sufficiently
More news about: DELFI Diagnostics
May 13, 2026, 08:00 ET Bankruptcy Attorney Chad Van Horn Surpasses 11,000 Case Filings, Donates $12,000 to American Lung Association on Road to 12,000
finishing in the top 10 out of 456 competitors.About the American Lung AssociationThe American Lung Association is the nation's leading organization dedicated to improving lung health and preventing lung disease through research, education, and advocacy. Learn more at
More news about: Van Horn Law Group, P.A.
May 13, 2026, 05:00 ET Synnovis and SOPHiA GENETICS Partner to Bring Blood-based Cancer Testing to Patients Across the U.K.
Ai-driven precision medicine, today announced a partnership with Synnovis, one of England's leading pathology providers, to bring liquid biopsy testing to lung and breast cancer patients across the U.K. as part of NHS England's '
More news about: SOPHiA GENETICS
May 13, 2026, 05:00 ET Synnovis and SOPHiA GENETICS Partner to Bring Blood-based Cancer Testing to Patients Across the U.K.
Ai-driven precision medicine, today announced a partnership with Synnovis, one of England's leading pathology providers, to bring liquid biopsy testing to lung and breast cancer patients across the U.K. as part of NHS England's '
More news about: SOPHiA GENETICS
May 12, 2026, 18:22 ET VAPORESSO Unveils XROS 6: Redefining MTL Efficiency with Industry-First 60-Second Smart Prime Technology
introduces a suite of "Instant Response" technologies. These features eliminate common delays and set a new standard for efficiency in the Mouth-to-Lung (MTL) category.
More news about: VAPORESSO
May 12, 2026, 18:22 ET VAPORESSO stellt XROS 6 vor: Neue Maßstäbe bei der MTL-Effizienz dank der branchenweit ersten „Smart Prime"-Technologie mit 60-Sekunden-Zyklus
„Instant-Response"-Technologien eingeführt. Diese Funktionen beseitigen häufige Verzögerungen und setzen neue Maßstäbe in Sachen Effizienz in der Kategorie „Mouth-to-Lung" (MTL).
More news about: VAPORESSO
May 12, 2026, 18:22 ET VAPORESSO Unveils XROS 6: Redefining MTL Efficiency with Industry-First 60-Second Smart Prime Technology
introduces a suite of "Instant Response" technologies. These features eliminate common delays and set a new standard for efficiency in the Mouth-to-Lung (MTL) category.
More news about: VAPORESSO
May 12, 2026, 10:00 ET Cizzle Bio CEO Bill Behnke Participates in National Oncology Commercialization Panel at City of Hope's 25th Ci4CC Summit
support early detection of lung cancer through identification of a tumor-associated protein variant strongly linked to early-stage disease. Developed from foundational research at the University of York, the minimally invasive test has demonstrated 95% sensitivity for Stage I lung cancer and 96% negative
More news about: Cizzle Bio
May 12, 2026, 09:59 ET Mary Alexander: Man Sues City of San Jose Over Crash That Left Him a Quadriplegic
action."As a result of the crash, Mr. Garmany was paralyzed from the neck down and quadriplegic. He suffered a fractured spine, fractured neck, punctured lung, broken ribs, and extensive lacerations and abrasions. His injuries have required significant medical treatment and are expected to have long-term consequences,
More news about: Mary Alexander & Associates
May 12, 2026, 09:30 ET Lung Cancer Research Foundation Grants Team Science Award Focused on Understanding and Treating Lung Cancers with HER2 Mutations
delivering more lasting and effective treatments for patients with HER2-mutant lung cancer.Lung cancers harboring HER2 mutations represent one of the most challenging subsets of oncogene-driven non–small cell lung cancers (NSCLC) to treat. Despite recent approvals of HER2-directed tyrosine kinase
More news about: Lung Cancer Research Foundation
May 12, 2026, 09:00 ET Harrington Discovery Institute Announces 2026 Scholar-Innovator Award Recipients
in CancerStephen Chan, MD, PhD – University of PittsburghNew Approach to Treatment of Pulmonary Hypertension, a Fatal Lung DiseaseSteven Chan, MD, PhD – University Health NetworkDrug to Cure a Blood Cancer, Acute Myeloid Leukemia, by Targeting
More news about: Harrington Discovery Institute
May 12, 2026, 08:32 ET Susan Wojcicki Foundation Launches to Advance Early Detection and Prevention of Lung Cancer
To Cancer, Lung Cancer Research Foundation, and other leading organizations to help accelerate progress. This includes initiatives like the Lung Cancer Genetics Study (LCGS) in partnership with more than 20 advocacy organizations, including GO2 for Lung Cancer, LUNGevity Foundation, and Lung Cancer Foundation
More news about: Susan Wojcicki Foundation
May 12, 2026, 08:30 ET IceCure Reports First Quarter 2026 Financial Results: ProSense® Sales Increase Substantially in the U.S. and North America
cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective option to surgical tumor removal that is easily performed in a relatively short procedure.
More news about: IceCure Medical
May 12, 2026, 07:00 ET Brainomix and Boehringer Ingelheim Advance Strategic Partnership in Pulmonary Fibrosis
deployments of e-Lung planned at numerous sites across the US.OXFORD, England and CHICAGO, May 12, 2026 /PRNewswire/ -- Brainomix, a global leader and pioneer of AI-powered imaging tools in lung fibrosis and stroke,
More news about: Brainomix
May 12, 2026, 07:00 ET New Altesa BioSciences Data: Vapendavir Demonstrates Anti-Viral Activity Against All Three Rhinovirus Species
utilization, and lung function.About Altesa BioSciences, Inc.Altesa BioSciences is a clinical-stage pharmaceutical company led by global experts in respiratory medicine and infectious diseases. Altesa is dedicated to improving the lives of people with chronic lung diseases
More news about: Altesa Biosciences Inc.
May 11, 2026, 11:48 ET /C O R R E C T I O N -- Anixa Biosciences, Inc./
breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms
More news about: Anixa Biosciences, Inc.
May 11, 2026, 09:00 ET Ranok Therapeutics Announces the Publication of Positive Phase 1a Clinical Results for KRAS G12D Inhibitor RNK08954 in Cancer Discovery
clinical activity. The overall objective response rate (ORR) was 28%, with a disease control rate (DCR) of 86%. Notably, patients with non-small cell lung cancer (NSCLC) achieved an ORR of 58.33% and a DCR of 100%. RNK08954 was generally well tolerated, with treatment-related adverse events consisting
More news about: Ranok Therapeutics
May 11, 2026, 08:00 ET Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy
potentially improve the efficacy of checkpoint inhibitors. This strategy includes initiating a study in the perioperative setting in non-small cell lung cancer (NSCLC) later this quarter. The Company believes OX40 agonism has the greatest potential to drive cure in earlier-stage disease settings, where
More news about: Inhibrx Biosciences, Inc.
May 11, 2026, 07:00 ET Leads Biolabs R&D Symposium: Platform Synergy and Multi-Mechanism Integration Reshape the Immuno-Oncology Landscape
best-in-class potential in registrational or Phase II clinical studies for extrapulmonary neuroendocrine carcinoma (EP-NEC), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and biliary tract cancer (BTC).Cold Tumor Efficacy: LBL-024 is poised to become the first approved drug
More news about: Nanjing Leads Biolabs Co., Ltd.